Clinical Trials Browser

Phase 3 × Metastatic Castration-resistant Prostate Cancer × enzalutamide × Clear all

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT04237584 2022-10-07

ESCALATE

Phase 3 Terminated

23 enrolled 11 charts

Metastatic Castration-resistant Prostate Cancer